Is IBRX a good stock to buy now? We came across a bullish thesis on ImmunityBio, Inc. on r/pennystocks by Bailey-96. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.’s share was trading at $10.00 as of March 3rd.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. IBRX is being positioned as a high-conviction bullish setup driven by an unusual combination of extreme short interest, accelerating fundamentals, and a rapid cadence of clinical and regulatory catalysts.
The stock currently carries short interest of roughly 40% of the float, or about 120 million shares, with approximately 10 days to cover, creating the structural conditions for a squeeze if volume expands. Cost to borrow is rising and failures-to-deliver are building, suggesting mounting pressure on short sellers.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
At the same time, the company’s Chairman and Chief Scientist, Patrick Soon-Shiong, has publicly indicated that multiple press releases are expected in close succession, limiting the typical strategy of shorting post-news spikes. Recent developments include positive non-small cell lung cancer (NSCLC) data announced on January 13 and Saudi FDA approval granted on January 14, with additional glioblastoma and CAR-NK updates still pending. Fundamentally, this is not a distressed meme situation.
Revenue surged 424% year over year to $32.1 million as ANKTIVA commercialization ramps, and the company holds $257 million in cash, materially reducing bankruptcy risk. While margins remain an area to monitor, the balance sheet provides runway as sales scale.
With improving business momentum intersecting with crowded bearish positioning, a sustained move above $3.00 could force covering activity that amplifies upside. The convergence of strong catalyst flow, strengthening revenue trends, and structural short pressure creates an asymmetric risk/reward skew favoring a potential breakout scenario.
Previously, we covered a bullish thesis on Moderna, Inc. (MRNA) by YouAlwaysHaveAChoice in February 2025, which highlighted virus-related catalysts, institutional accumulation, technical reversal signals, and strong options activity. MRNA’s stock price has appreciated by approximately 49.72% since our coverage. Bailey-96 shares a similar view but emphasizes on extreme short interest, rising cost to borrow, accelerating revenue growth, and imminent clinical catalysts driving a potential short squeeze in ImmunityBio.
ImmunityBio, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 19 hedge fund portfolios held IBRX at the end of the fourth quarter which was 18 in the previous quarter. While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
